On March 28, 2018 Arcus Biosciences (NYSE: RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, reported that five abstracts have been accepted for poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2018 Annual Meeting to be held April 14-18, 2018 in Chicago, Illinois. The presentations at AACR (Free AACR Whitepaper) cover three of our clinical and preclinical product candidates including our dual adenosine receptor antagonist, AB928; our PD-1 antibody, AB122; and our small molecule CD73 inhibitor, AB680 (Press release, Arcus Biosciences, MAR 15, 2018, View Source [SID1234525079]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Data to be presented include:
AB928:
Title: Pharmacokinetic-Pharmacodynamic relationship for AB928, a dual antagonist of the A2aR and A2bR adenosine receptors – abstract #3769
Title: Combining adenosine receptor inhibition with AB928 and chemotherapy results in greater immune activation and tumor control – abstract #5556
AB122:
Title: Preclinical characterization of GLS-010 (AB122), a fully human clinical-stage anti-PD-1 antibody – abstract #4561
AB680:
Title: CD73 inhibitors (CD73i) reverse the AMP/adenosine-mediated impairment of immune effector cell activation by Immune Checkpoint Inhibitors (ICI) – abstract #710
Title: Discovery and characterization of AB680, a potent and selective small-molecule CD73 inhibitor for cancer immunotherapy – abstract #4886
Additional information – including presentation schedule and full abstracts – can be found at www.aacr.org.